Novartis’s multiple sclerosis pill Gilenya failed for a second time to gain the backing of the UK’s health-cost agency, denting the company’s ambitions to turn the drug into a blockbuster. (Times) >
Novartis’s multiple sclerosis pill Gilenya failed for a second time to gain the backing of the UK’s health-cost agency, denting the company’s ambitions to turn the drug into a blockbuster. (Times) >

Email medica@penhire.ie for a quote. We'll have you right in no time.
TESTIMONIAL: "Paul was commissioned to assist with writing a lay summary of a research grant proposal for a piece of laboratory equipment. He phrased advanced science concepts in a way that could be easily understood, and which was a pleasure to read."